FDA Hemp THC Regulation: Federal Rules, Limits, and Compliance Guide

Executive Summary

The U.S. Food and Drug Administration is preparing comprehensive regulations for hemp-derived products that will impose stricter limits on THC content, responding to congressional pressure and a proliferation of intoxicating hemp products in the marketplace. The forthcoming rule represents the most significant federal intervention in the hemp market since the 2018 Farm Bill legalized hemp cultivation and removed it from the Controlled Substances Act. The FDA's action comes as Congress considers statutory amendments that would further tighten restrictions on delta-8 THC, delta-10 THC, THC-O, and other semi-synthetic cannabinoids derived from CBD isolate extracted from hemp. Industry stakeholders estimate the hemp-derived cannabinoid market reached $28 billion in retail sales in 2025, with intoxicating products accounting for approximately $8 billion of that total. The regulatory framework will affect thousands of manufacturers, retailers, and farmers across all 50 states, potentially reshaping the legal cannabis landscape by closing loopholes that have allowed psychoactive hemp products to proliferate in states without adult-use marijuana programs. Consumer safety advocates have pressed for federal action following reports of adverse events and the absence of quality control standards, while hemp industry groups warn that overly restrictive rules could eliminate legitimate businesses and drive consumers to unregulated black markets.

Why This Matters

FDA hemp THC regulation will determine the fate of an $8 billion intoxicating hemp product sector and affect the competitive dynamics between state-licensed marijuana markets and federally legal hemp markets. The regulatory outcome carries profound implications for multiple stakeholder groups operating in overlapping but legally distinct markets. For state-licensed cannabis operators, the FDA rule could level a playing field that has tilted toward hemp competitors. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have repeatedly cited hemp-derived delta-8 THC products as competitive threats that avoid the tax burden of Internal Revenue Code Section 280E, which prohibits marijuana businesses from deducting ordinary business expenses. A 2025 analysis by cannabis financial services firm Viridian Capital Advisors found that states with unrestricted hemp-derived THC sales saw 12-18% lower per-capita spending at licensed dispensaries compared to states that banned such products. Hemp farmers and processors face existential uncertainty. The U.S. Department of Agriculture reported that 54,152 licensed hemp growers cultivated 127,960 acres in 2025, with approximately 35% of that acreage dedicated to cannabinoid extraction rather than fiber or grain production. Tighter THC limits could eliminate the economic viability of growing hemp for CBD extraction if processors cannot sell the delta-8 THC and other derivatives that currently provide margin. The National Hemp Association estimated in June 2026 that proposed restrictions could eliminate 40,000 jobs and $4.2 billion in economic activity. Consumer access represents another critical dimension. In states including Texas, Georgia, and North Carolina—where adult-use marijuana remains illegal—hemp-derived THC products have provided the only legal access to intoxicating cannabinoids. The Southern Hemp Coalition reported that approximately 18,000 retail locations across 15 southern states sell hemp-derived delta-8 THC products, serving an estimated 4.2 million regular consumers who lack access to state-licensed dispensaries. Public health and safety concerns have driven regulatory momentum. The FDA received 2,842 adverse event reports related to delta-8 THC products between January 2021 and May 2026, including 104 hospitalizations. The American Association of Poison Control Centers documented 7,362 calls regarding hemp-derived cannabinoid exposures in 2025, a 340% increase from 2022. Pediatric exposures accounted for 28% of cases, often involving edible products with packaging that resembled conventional candy.

Background and History

The current regulatory crisis stems from a legal gap created when the 2018 Farm Bill legalized hemp without addressing the intoxicating potential of hemp-derived cannabinoids.

The 2018 Farm Bill and Hemp Legalization

On December 20, 2018, President Donald Trump signed the Agriculture Improvement Act of 2018 into law, fundamentally altering the legal status of hemp. Section 10113 of the legislation amended the Agricultural Marketing Act of 1946 to establish a federal regulatory framework for hemp production and removed hemp from Schedule I of the Controlled Substances Act. The statute defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The 0.3% delta-9 THC threshold had originated in a 1976 taxonomic paper by Canadian plant scientists Ernest Small and Arthur Cronquist, who used the figure to distinguish fiber and oilseed cultivars from drug cultivars. The threshold was never intended as a safety standard or potency limit for finished consumer products. Senate Majority Leader Mitch McConnell of Kentucky championed the hemp provisions, viewing the crop as an economic opportunity for tobacco farmers in his state and across the South. The 2018 Farm Bill assigned regulatory authority to two agencies: the USDA received jurisdiction over hemp cultivation and agricultural production, while the FDA retained authority over hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act.

Early CBD Market Development (2019-2020)

Following hemp legalization, a CBD market emerged rapidly. The Hemp Business Journal estimated the total U.S. hemp-derived CBD market reached $4.6 billion in retail sales in 2019, growing to $7.1 billion in 2020. Products included tinctures, topicals, capsules, and edibles marketed for wellness purposes including sleep, anxiety, and inflammation. The FDA issued warning letters to 15 companies in November 2019 for making unsubstantiated health claims about CBD products, including claims to treat cancer, Alzheimer's disease, and opioid withdrawal. The agency established a working group to explore potential regulatory pathways for CBD in food and dietary supplements but made no formal determinations. During this period, hemp-derived products contained primarily CBD and trace amounts of delta-9 THC below the 0.3% statutory threshold. The products were non-intoxicating and did not compete directly with state-licensed marijuana markets.

Delta-8 THC Emergence (2020-2021)

In late 2020, manufacturers began producing and marketing delta-8 THC products derived from hemp. Delta-8 THC is a naturally occurring cannabinoid found in cannabis plants in trace amounts—typically less than 1% of total cannabinoid content. Manufacturers developed processes to convert CBD isolate extracted from hemp into delta-8 THC through chemical reactions involving acids, heat, and solvents. The resulting delta-8 THC products produced intoxicating effects similar to delta-9 THC, though users generally reported milder psychoactive intensity. Manufacturers argued the products were legal under the 2018 Farm Bill because they were "derivatives" of hemp and contained less than 0.3% delta-9 THC, even though the total THC content (including delta-8) often exceeded 90% in concentrated forms. The DEA issued an Interim Final Rule on August 21, 2020, implementing the 2018 Farm Bill's hemp provisions. The rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances," but did not specifically address delta-8 THC or clarify whether cannabinoids produced through chemical conversion of hemp-derived CBD qualified as "synthetic." Delta-8 THC products proliferated rapidly. BDS Analytics estimated the delta-8 THC market reached $2 billion in sales in 2021, with products available in gas stations, convenience stores, smoke shops, and online retailers across states where marijuana remained illegal.

State Regulatory Responses (2021-2023)

States responded inconsistently to hemp-derived intoxicating products. Alaska, Arizona, Arkansas, Colorado, Delaware, Idaho, Iowa, Kentucky, Mississippi, Montana, New York, North Dakota, Rhode Island, Utah, Vermont, and Washington enacted restrictions or outright bans on delta-8 THC between 2021 and 2023. Other states including Texas, Georgia, North Carolina, Tennessee, and Florida allowed delta-8 THC sales to continue, though some imposed age restrictions or labeling requirements. Michigan and Oregon—both adult-use marijuana states—permitted delta-8 THC sales but required products to be sold through licensed marijuana retailers and tested to the same standards as marijuana products. The patchwork of state laws created regulatory arbitrage opportunities. Manufacturers in permissive states shipped products across state lines, arguing that the 2018 Farm Bill preempted state restrictions on hemp and hemp-derived products. Several legal challenges ensued, with courts reaching conflicting conclusions about the scope of federal preemption.

Expansion to Novel Cannabinoids (2022-2024)

As states restricted delta-8 THC, manufacturers introduced additional hemp-derived intoxicating cannabinoids including delta-10 THC, THC-O acetate, THC-P, and HHC (hexahydrocannabinol). Each compound was produced through chemical conversion of CBD isolate using proprietary processes. The FDA issued warning letters to five companies in February 2023 regarding THC-O acetate products, stating that the compound did not occur naturally in cannabis and therefore did not qualify as a hemp derivative under the 2018 Farm Bill. The agency characterized THC-O as a synthetic controlled substance, but enforcement remained limited. The hemp-derived cannabinoid market continued expanding. The National Hemp Association estimated total sales of intoxicating hemp products reached $6.2 billion in 2023 and $8.1 billion in 2024, with growth concentrated in states without adult-use marijuana programs.

Congressional Pressure and Proposed Legislation (2025-2026)

Members of Congress from both parties expressed concern about intoxicating hemp products. On March 14, 2025, Representatives Mary Miller (R-IL) and Chellie Pingree (D-ME) introduced the Hemp and Hemp-Derived Consumer Products Market Stabilization Act, which would have amended the 2018 Farm Bill to limit total THC content in hemp-derived products to 0.3% on a dry weight basis, encompassing all THC isomers including delta-8, delta-10, and others. The bill did not advance, but similar language appeared in the 2026 Farm Bill reauthorization discussions. The House Agriculture Committee held hearings in April and May 2026 featuring testimony from the FDA, USDA, state agriculture commissioners, hemp industry representatives, and marijuana industry groups. FDA Principal Deputy Commissioner Namandjé Bumpus testified on May 8, 2026, that the agency was developing a proposed rule to address hemp-derived products and anticipated publication in the Federal Register by late 2026. Bumpus stated that the rule would establish THC limits, manufacturing standards, labeling requirements, and age restrictions, but did not provide specific details. Senate Majority Leader Chuck Schumer announced on June 18, 2026, that the Senate version of the Farm Bill reauthorization would include provisions requiring the FDA to finalize hemp product regulations within 180 days of enactment and establishing a statutory limit of 0.3% total THC in finished hemp-derived consumer products. The provision represented a significant tightening from the current 0.3% delta-9 THC standard.

Key Players

Food and Drug Administration

The FDA holds statutory authority over hemp-derived products intended for human consumption under the Federal Food, Drug, and Cosmetic Act. The agency's Center for Food Safety and Applied Nutrition oversees dietary supplements and food additives, while the Center for Drug Evaluation and Research regulates pharmaceutical applications of cannabinoids. FDA Commissioner Robert Califf has stated publicly that the agency lacks adequate resources to comprehensively regulate the hemp-derived product market and has requested additional appropriations from Congress. The agency's proposed rule will likely establish manufacturing standards under current Good Manufacturing Practices, require adverse event reporting, set serving size limits, mandate child-resistant packaging, and restrict marketing claims.

U.S. Department of Agriculture

The USDA regulates hemp cultivation through the Agricultural Marketing Service, which oversees state and tribal hemp production plans. The department's role focuses on pre-harvest testing to ensure delta-9 THC levels remain below 0.3% and does not extend to post-harvest processing or finished products. USDA Secretary Tom Vilsack has advocated for clear federal standards to provide certainty for farmers, noting that regulatory ambiguity has created volatility in hemp commodity prices.

Drug Enforcement Administration

The DEA maintains that synthetically derived THC remains a Schedule I controlled substance under 21 U.S.C. § 812, but has not actively enforced against hemp-derived delta-8 THC manufacturers. The agency's August 2020 Interim Final Rule created interpretive questions about whether chemical conversion of hemp-derived CBD constitutes "synthetic" production. DEA Administrator Anne Milgram stated in congressional testimony on April 23, 2026, that the agency defers to the FDA on hemp product regulation but stands ready to enforce against products that fall outside the statutory hemp definition.

Hemp Industry Groups

The U.S. Hemp Roundtable, National Hemp Association, and Hemp Industries Association represent cultivators, processors, and manufacturers. These organizations have advocated for federal regulation to establish uniform national standards while preserving market access for compliant products. The groups support age restrictions, labeling requirements, and manufacturing standards but oppose total THC limits that would effectively ban intoxicating hemp products. The U.S. Hemp Roundtable released a white paper in March 2026 proposing a 5 mg THC per serving limit for edibles and a 50 mg limit per package, modeled on regulations in Colorado and other adult-use states.

Cannabis Industry Groups

The Cannabis Trade Federation, National Cannabis Industry Association, and American Trade Association for Cannabis and Hemp—representing state-licensed marijuana businesses—have lobbied for restrictions on hemp-derived intoxicating products. These groups argue that delta-8 THC and similar products circumvent state regulatory frameworks, avoid taxation, and undermine public health protections including testing requirements and potency limits. The organizations support the 0.3% total THC limit proposed in congressional legislation.

State Regulators

The National Association of State Departments of Agriculture has called for federal clarity on hemp product standards to reduce interstate commerce conflicts. State cannabis control boards including those in California, Colorado, and Washington have reported enforcement challenges when hemp-derived products that would be illegal under state marijuana regulations are sold through non-licensed retailers.

Legal and Regulatory Framework

The legal status of hemp-derived intoxicating products hinges on the interaction between the 2018 Farm Bill's hemp definition, the Controlled Substances Act, and the Federal Food, Drug, and Cosmetic Act. The Agricultural Improvement Act of 2018, codified at 7 U.S.C. § 1639o, defines hemp as cannabis with "a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The statute does not address delta-8 THC, delta-10 THC, or other THC isomers, creating the interpretive gap that manufacturers have exploited. The Controlled Substances Act, 21 U.S.C. § 812, lists "tetrahydrocannabinols" in Schedule I without distinguishing between isomers. The DEA's August 21, 2020, Interim Final Rule stated that "for synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance. All synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The rule defined "synthetically derived" as "a substance that has been created by a chemical reaction that either changes the molecular structure of any compound derived from the plant Cannabis sativa L. or creates a new chemical compound." This definition creates ambiguity for delta-8 THC produced by converting CBD through chemical processes. Manufacturers argue that because the starting material (CBD) and ending product (delta-8 THC) both occur naturally in cannabis, the conversion does not create a "new chemical compound" and therefore does not qualify as synthetic. The DEA has not issued clarifying guidance or brought enforcement actions that would test this interpretation in court. The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., grants the FDA authority to regulate food, dietary supplements, drugs, and cosmetics. Section 321(ff) of the Act, added by the 2018 Farm Bill, excludes hemp and hemp-derived CBD from the definition of marijuana but does not exempt hemp products from FDA regulation. The agency has authority under 21 U.S.C. § 342(a)(2)(C) to deem a food adulterated if it contains an unsafe food additive, and under 21 U.S.C. § 331 to prohibit the introduction of adulterated or misbranded products into interstate commerce. The FDA has not established delta-8 THC or other hemp-derived cannabinoids as Generally Recognized as Safe (GRAS) for use in food, nor approved them as food additives through the petition process outlined in 21 C.F.R. § 171. Technically, this means hemp-derived intoxicating products currently in commerce violate the Federal Food, Drug, and Cosmetic Act, but the FDA has exercised enforcement discretion and issued warning letters rather than pursuing seizures or injunctions. State laws add additional complexity. The Supremacy Clause of the U.S. Constitution, Article VI, Clause 2, establishes that federal law preempts conflicting state law. The 2018 Farm Bill includes language at 7 U.S.C. § 1639o(a)(2) stating that states and tribes may adopt laws regarding hemp production that are "more stringent" than federal requirements. Courts have not definitively resolved whether this provision allows states to ban hemp-derived products that are legal under federal law, or whether such bans conflict with the Farm Bill's intent to establish a national hemp market.

State-by-State Breakdown

States have adopted widely divergent approaches to regulating hemp-derived intoxicating products, creating a fragmented national market.

States with Comprehensive Bans

Alaska prohibited delta-8 THC and all hemp-derived intoxicating cannabinoids through emergency regulations adopted by the Marijuana Control Board in September 2021. The state requires all THC products to be sold through licensed marijuana retailers and tested to Alaska marijuana standards. Colorado enacted House Bill 22-1317 in May 2022, requiring hemp-derived products containing detectable amounts of any THC isomer to be sold exclusively through licensed marijuana retailers. The law established a 2 mg THC per serving limit and 10 mg per package limit for edibles sold through the regulated market. New York banned delta-8 THC sales outside the licensed marijuana market through guidance issued by the Office of Cannabis Management in October 2021. The state's Cannabis Law restricts all "adult-use cannabis products" to licensed retailers, defining such products to include any item containing more than 0.3% total THC.

States with Partial Restrictions

Texas allows delta-8 THC sales but requires manufacturers to register with the Department of State Health Services and comply with labeling requirements under Texas Health and Safety Code § 443. The state prohibits sales to individuals under 21 and requires child-resistant packaging. Texas does not impose potency limits or testing requirements. Georgia permits hemp-derived THC products under the Georgia Hemp Farming Act but requires products to contain less than 0.3% delta-9 THC on a dry weight basis. The state does not restrict other THC isomers. Age restrictions of 18+ apply, and products cannot make therapeutic claims without FDA approval. Florida allows delta-8 THC sales with minimal state oversight. The state's hemp program, administered by the Department of Agriculture and Consumer Services, focuses on cultivation rather than finished products. Local jurisdictions including Miami-Dade County have enacted their own restrictions.

States with Permissive Frameworks

North Carolina has not enacted specific restrictions on hemp-derived intoxicating products beyond requiring compliance with the 2018 Farm Bill's 0.3% delta-9 THC limit. The state's hemp program, established under N.C. Gen. Stat. § 106-568.51, does not address delta-8 THC or other isomers. Tennessee allows hemp-derived cannabinoid sales under the Tennessee Hemp and Hemp-Derived Cannabinoid Act, which established a regulatory framework in 2023 requiring manufacturers to register with the state, conduct testing for contaminants, and comply with labeling standards. The law permits products containing up to 0.3% delta-9 THC but does not restrict total THC content. Ohio permitted hemp-derived delta-8 THC sales until November 2023, when the state legislature passed House Bill 86 requiring all intoxicating hemp products to be sold through the state's medical marijuana dispensary system. The law takes effect in January 2027, creating a transition period for existing retailers.

Market and Business Implications

FDA regulation imposing strict THC limits would eliminate the majority of current hemp-derived intoxicating product sales and force thousands of businesses to exit the market or pivot to non-intoxicating formulations. The hemp-derived cannabinoid sector has developed a distinct supply chain separate from state-licensed marijuana markets. Biomass suppliers cultivate high-CBD hemp under USDA-approved state plans, selling raw material to extraction facilities at prices ranging from $200 to $600 per pound depending on CBD content. Extractors produce CBD isolate—a crystalline powder typically 99%+ pure CBD—which wholesales for $1,000 to $3,000 per kilogram as of June 2026. Chemical conversion facilities purchase CBD isolate and transform it into delta-8 THC, delta-10 THC, or other cannabinoids through proprietary processes. The conversion typically involves dissolving CBD in a solvent, adding an acid catalyst, applying heat, and purifying the resulting product through distillation. Wholesale delta-8 THC distillate trades at $800 to $2,500 per kilogram depending on purity and volume. Finished product manufacturers formulate the distillate into vape cartridges, edibles, tinctures, and other consumer goods. Distribution occurs through wholesale networks serving smoke shops, convenience stores, gas stations, and online retailers. The market structure differs fundamentally from state-licensed marijuana markets, which typically require vertical integration or strict seed-to-sale tracking. A regulatory framework limiting total THC to 0.3% would render this supply chain economically unviable for intoxicating products. A 0.3% limit would restrict a 10-gram edible product to 30 mg total THC—equivalent to three 10 mg servings under typical adult-use marijuana state standards. While such products could serve the low-dose market, they would not compete effectively with state-licensed marijuana products or command the premium pricing that has driven hemp industry margins. Industry analysts project that 60-75% of current hemp-derived cannabinoid manufacturers would exit the market under a 0.3% total THC limit. Whitney Economics, a cannabis consulting firm, estimated in a May 2026 report that such regulation would eliminate $5.8 billion in annual sales and 38,000 jobs, primarily in states without adult-use marijuana programs. Conversely, state-licensed marijuana operators would likely benefit from reduced competition. Multi-state operators have reported that hemp-derived delta-8 THC products priced 30-50% below equivalent marijuana products have eroded market share in states where both are available. Curaleaf Holdings reported in its Q1 2026 earnings call that same-store sales in Florida—a medical marijuana state with permissive hemp laws—grew 8% year-over-year compared to 14% in Pennsylvania, which banned delta-8 THC in 2022. The regulatory outcome will also affect capital allocation in the cannabis sector. Equity investors have largely avoided hemp-derived cannabinoid companies due to regulatory uncertainty, preferring state-licensed operators with clearer legal standing. Debt financing for hemp businesses has become scarce as banks assess reputational and legal risks. Stricter federal regulation could paradoxically improve access to capital for compliant hemp businesses by establishing clear rules, while simultaneously reducing the total addressable market. Tax implications represent another critical business dimension. Hemp businesses currently deduct ordinary business expenses under federal tax law, while marijuana businesses cannot due to Internal Revenue Code Section 280E, which prohibits deductions for businesses trafficking in Schedule I or II controlled substances. This creates an effective tax rate of 70-85% for marijuana operators compared to 25-30% for hemp businesses. If FDA regulation establishes that compliant hemp-derived products are legal, the tax advantage would persist, benefiting low-dose hemp product manufacturers who can operate within the new limits.

What Experts Say

Stakeholders across the cannabis and hemp industries have expressed sharply divergent views on appropriate federal regulation, reflecting conflicting economic interests and policy priorities. The U.S. Hemp Roundtable has advocated for federal standards that preserve market access for intoxicating hemp products while establishing safety guardrails. Jonathan Miller, the organization's general counsel, stated in May 2026 congressional testimony that "a blanket prohibition on hemp-derived cannabinoids would eliminate consumer choice, destroy legitimate businesses, and drive demand to unregulated black markets." Miller proposed a framework modeled on alcohol regulation, with serving size limits, age restrictions, and labeling requirements but no categorical ban on intoxicating effects. The National Cannabis Industry Association has taken the opposite position, supporting the 0.3% total THC limit in proposed congressional legislation. Aaron Smith, the organization's chief executive, said according to a March 2026 press release that "intoxicating hemp products circumvent the regulatory frameworks that voters approved in 24 states and create an unlevel playing field where licensed businesses pay taxes and follow strict rules while hemp companies operate with minimal oversight." Smith characterized delta-8 THC as a "loophole product" that undermines state cannabis programs. Public health researchers have emphasized safety concerns. Danielle Ompad, an epidemiologist at New York University's School of Global Public Health, published research in the American Journal of Public Health in April 2026 documenting that 23% of delta-8 THC products tested contained contaminants including heavy metals, pesticides, or residual solvents exceeding safety thresholds. Ompad stated in an interview with the journal that "the absence of manufacturing standards and testing requirements creates serious risks, particularly for vulnerable populations including pregnant women and adolescents." State agriculture officials have called for federal clarity to resolve interstate commerce conflicts. Kentucky Agriculture Commissioner Jonathan Shell said according to a February 2026 statement that "farmers need to know what they can legally grow and sell across state lines, and right now the rules are different in every state, which makes it impossible to build a sustainable market." Legal scholars have debated the scope of FDA authority and constitutional limits on federal regulation. Robert Mikos, a law professor at Vanderbilt University and cannabis law expert, argued in a February 2026 law review article that the FDA has clear statutory authority under the Federal Food, Drug, and Cosmetic Act to regulate hemp-derived products but faces practical enforcement challenges given limited resources and the diffuse nature of the market. Mikos suggested that Congress should provide explicit direction rather than relying on agency rulemaking to resolve politically contentious questions about THC limits. Consumer advocates have emphasized the need for product transparency and accurate labeling. Maritza Perez, director of the Drug Policy Alliance's Office of National Affairs, stated in April 2026 congressional testimony that "consumers deserve to know what they're purchasing and consuming, and current hemp products often lack basic information about cannabinoid content, serving sizes, and potential effects." Perez supported federal regulation but cautioned against overly restrictive limits that would eliminate harm reduction options for people in states without legal marijuana access.

What's Next

The FDA is expected to publish a Notice of Proposed Rulemaking in the Federal Register by December 2026, triggering a 60-90 day public comment period before finalizing regulations in 2027. The rulemaking process under the Administrative Procedure Act, 5 U.S.C. § 553, requires the agency to provide notice of proposed rules, accept public comments, and respond to significant issues raised before issuing a final rule. The FDA typically receives thousands of comments on controversial regulations, which the agency must review and address in the final rule's preamble. Industry observers anticipate the proposed rule will include several key elements: A total THC limit, likely between 0.3% and 0.5% on a dry weight basis, encompassing all THC isomers including delta-8, delta-9, delta-10, and others. This would effectively prohibit intoxicating hemp products while allowing low-dose formulations. Manufacturing standards requiring compliance with current Good Manufacturing Practices as outlined in 21 C.F.R. § 117, including hazard analysis, process controls, and sanitation requirements. Testing requirements for potency, pesticides, heavy metals, microbial contaminants, and residual solvents, with results disclosed on product labels or certificates of analysis. Labeling mandates including cannabinoid content, serving size, total servings per package, ingredient lists, and standardized warning statements about psychoactive effects and impairment. Age restrictions prohibiting sales to individuals under 21, with retailer verification requirements. Marketing restrictions banning health claims not approved by the FDA and prohibiting packaging or advertising that appeals to minors. Adverse event reporting requirements obligating manufacturers to submit reports of serious adverse events to the FDA within 15 days. The timeline for final rule implementation will depend on the complexity of comments received and potential legal challenges. If the FDA publishes a proposed rule in December 2026 and finalizes it by mid-2027, compliance deadlines would likely phase in over 12-24 months to allow businesses time to reformulate products or exit the market. Congressional action could accelerate or alter this timeline. If the 2026 Farm Bill reauthorization includes statutory THC limits and mandates FDA rulemaking within 180 days, the agency would face a compressed schedule. The House Agriculture Committee approved its version of the Farm Bill on June 27, 2026, including hemp provisions, but the Senate had not voted as of early July 2026. Legal challenges are virtually certain once the FDA issues a final rule. Hemp industry groups will likely argue that the agency exceeded its statutory authority, that the rule is arbitrary and capricious under the Administrative Procedure Act, or that it conflicts with the 2018 Farm Bill's intent to establish a legal hemp market. Such challenges would be filed in federal district court and could take 18-36 months to resolve through the appellate process. State regulatory responses will also evolve. States that currently allow hemp-derived intoxicating products may adopt their own restrictions in anticipation of federal rules, while states with existing bans may maintain them regardless of FDA action. The National Conference of State Legislatures reported that 28 state legislatures were considering hemp-related bills as of June 2026. Market consolidation appears inevitable. Smaller manufacturers lacking resources to comply with new testing, labeling, and manufacturing requirements will exit, while larger operators with quality control infrastructure will gain market share in the compliant low-dose segment. Some hemp companies may seek acquisition by or partnership with state-licensed marijuana operators to access regulated distribution channels.

Further Reading

• Agriculture Improvement Act of 2018, Public Law 115-334, 132 Stat. 4490 (December 20, 2018) — https://www.congress.gov/bill/115th-congress/house-bill/2
• DEA Interim Final Rule, Implementation of the Agriculture Improvement Act of 2018, 85 Fed. Reg. 51639 (August 21, 2020) — https://www.federalregister.gov/documents/2020/08/21/2020-18387/implementation-of-the-agriculture-improvement-act-of-2018
• FDA Statement on Delta-8 THC (May 4, 2022) — https://www.fda.gov/consumers/consumer-updates/5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc
• USDA National Hemp Report (2025) — https://www.ams.usda.gov/rules-regulations/hemp
• Congressional Research Service, "The Farm Bill and Hemp" (Updated March 2026) — https://crsreports.congress.gov
• U.S. Hemp Roundtable White Paper, "A Framework for Federal Hemp Regulation" (March 2026) — https://www.hempsupporter.com
• National Cannabis Industry Association, "The Delta-8 Loophole: How Intoxicating Hemp Products Undermine State Cannabis Programs" (February 2026) — https://thecannabisindustry.org
• Ompad et al., "Contaminant Testing of Delta-8 THC Products," American Journal of Public Health 116:4 (April 2026) — https://ajph.aphapublications.org
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. — https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act

  Frequently asked questions

  What is the FDA's current position on THC in hemp products?

  The FDA has not approved THC or CBD as food additives or dietary supplement ingredients. Under the Federal Food, Drug, and Cosmetic Act, the agency prohibits adding drug ingredients to food, and because CBD was investigated as a drug before being marketed in foods, it cannot be legally added to food or supplements without FDA authorization. The FDA continues to evaluate regulatory pathways while warning companies against unsubstantiated health claims and mislabeled THC content.

  How does the 2018 Farm Bill affect FDA hemp regulation?

  The 2018 Farm Bill removed hemp (cannabis with ≤0.3% delta-9 THC by dry weight) from Schedule I of the Controlled Substances Act, legalizing its cultivation and interstate commerce. However, the law explicitly preserved the FDA's authority to regulate hemp-derived products as foods, drugs, cosmetics, and dietary supplements. This created a legal market for hemp cultivation while maintaining FDA oversight of consumer products, resulting in ongoing regulatory gaps the agency is working to address.

  What THC limits does the FDA enforce for hemp products?

  The FDA enforces the 2018 Farm Bill's definition requiring hemp to contain no more than 0.3% delta-9 THC on a dry weight basis. However, the agency has not established specific THC limits for finished consumer products like foods, beverages, or topicals. Congressional proposals and pending FDA rulemaking suggest tighter restrictions may establish per-serving THC limits, total THC testing requirements (including delta-8 and other isomers), and stricter manufacturing controls to prevent intoxicating products from reaching consumers.

  Can hemp-derived CBD products be legally sold as dietary supplements?

  No. The FDA has stated that CBD cannot be sold as a dietary supplement because it was investigated as a drug (Epidiolex) before being marketed in supplements, violating the drug exclusion rule under 21 U.S.C. § 321(ff)(3)(B). The agency has issued warning letters to companies marketing CBD supplements and has not established a regulatory pathway for CBD in dietary supplements, though it continues to evaluate options and has requested public comment on potential frameworks.

  What is the difference between hemp and marijuana under federal law?

  Federal law distinguishes hemp from marijuana solely by THC concentration. Hemp is cannabis containing ≤0.3% delta-9 THC by dry weight and is legal under the 2018 Farm Bill. Marijuana is cannabis exceeding this threshold and remains a Schedule I controlled substance under the Controlled Substances Act. Both are the same plant species (Cannabis sativa), but the legal distinction determines whether cultivation, processing, and sale are federally lawful or subject to criminal penalties.

  How does the FDA regulate delta-8 THC and other hemp-derived cannabinoids?

  The FDA has not authorized delta-8 THC, delta-10 THC, or other semi-synthetic cannabinoids derived from hemp CBD. The agency has issued consumer warnings about delta-8 THC products, citing concerns about manufacturing processes, contamination, and intoxicating effects. Because these compounds are often synthesized from CBD through chemical conversion, they may not qualify as naturally occurring hemp derivatives, potentially subjecting them to additional regulatory scrutiny as unapproved food additives or adulterated products under FDA enforcement authority.

  What enforcement actions has the FDA taken against hemp THC products?

  The FDA has issued dozens of warning letters to companies marketing hemp-derived CBD and THC products with unsubstantiated health claims, including claims to treat cancer, Alzheimer's, opioid addiction, and COVID-19. The agency has also warned against products marketed to children, mislabeled THC content, and violations of the drug exclusion rule. Enforcement priorities include products posing serious health risks, targeting vulnerable populations, or making egregious therapeutic claims without adequate evidence or approval.

  Are states allowed to impose stricter hemp THC regulations than the FDA?

  Yes. The 2018 Farm Bill allows states to implement their own hemp regulatory programs, which may be more restrictive than federal standards. Many states have established lower THC limits, banned intoxicating hemp products, required additional testing, or prohibited certain product types like delta-8 THC. State regulations can create compliance challenges for interstate commerce, as products legal in one state may be prohibited in another, requiring manufacturers to navigate a patchwork of state and federal requirements.

  What is Congress doing to address hemp THC regulation gaps?

  Congress has introduced multiple bills to clarify hemp THC regulation, including proposals to establish per-serving THC limits, ban intoxicating hemp products, require FDA pre-market review for hemp-derived foods and supplements, and provide the FDA with explicit authority to regulate hemp cannabinoids. Some legislation would impose stricter definitions of hemp, mandate total THC testing (not just delta-9), and create penalties for non-compliant products. These efforts reflect concerns about unregulated intoxicating hemp products entering the market.

  What should hemp businesses know about FDA compliance?

  Hemp businesses must avoid marketing products with drug claims, ensure THC content complies with the 0.3% limit, accurately label cannabinoid content, implement good manufacturing practices, and avoid targeting children. Companies should not market CBD as a dietary supplement, make unsubstantiated health claims, or sell products that could be confused with FDA-approved drugs. Maintaining third-party lab testing, proper documentation, and awareness of both federal FDA rules and state-specific requirements is essential for compliance and avoiding enforcement actions.

  Will the FDA create a legal pathway for CBD in food and supplements?

  The FDA has stated it is evaluating regulatory pathways for CBD in food and dietary supplements but has not committed to a timeline. The agency has requested public comment, conducted research on CBD safety, and acknowledged industry and consumer interest. However, significant safety questions remain regarding long-term use, drug interactions, and effects on vulnerable populations. Any pathway would likely require pre-market review, safety data, and manufacturing standards, making authorization a multi-year process requiring Congressional action or extensive rulemaking.

  How do FDA hemp rules affect interstate commerce and shipping?

  Hemp products meeting the 0.3% delta-9 THC limit can be shipped interstate under the 2018 Farm Bill, but FDA regulations still apply. Products making drug claims, containing unapproved additives, or violating labeling requirements can be seized or refused entry. Additionally, state laws may restrict certain hemp products even if federally compliant, and shipping carriers may impose their own restrictions. Businesses must ensure products comply with FDA rules, destination state laws, and carrier policies to avoid shipment delays, seizures, or legal liability.

  FDA regulationhempTHC limitsCBDfederal lawcompliance